2025 withdrawal proposal for pharmalgen for the treatment of bee and wasp venom allergy (TA246)
Open for comments Open until Request commenting lead permission
We have updated this service so that members of the same organisation can now collaborate on a joint online response.
Read our blog to learn more.
Basis for the withdrawal proposal
Pharmalgen no longer has a marketing authorisation for the treatment of bee and wasp venom allergy in the UK.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation